Shares of LEADS BIOLABS-B (09887) surged more than 15% during the morning trading session.

As of the latest update, the stock is up 6.39%, trading at HK$63.30 with a turnover of HK$167 million.

The company announced that six of its latest research findings have been selected for presentation at the 2026 European Society for Medical Oncology Annual Meeting.

Among the six selected studies, two have been chosen for the highest-level oral presentations, while four will be presented as posters, covering treatment areas such as extrapulmonary neuroendocrine carcinoma, biliary tract cancer, and relapsed/refractory multiple myeloma.

Furthermore, the company has been granted a Late-Breaking Abstract status and will submit the full LBA by September 2026.

The company had previously announced that LBL-024 for first-line non-small cell lung cancer was selected for an oral presentation at the World Conference on Lung Cancer this September.

On July 10, the company announced that the Biologics License Application for its self-developed PD-L1/4-1BB bispecific antibody, LBL-024, as a monotherapy for advanced, previously treated extrapulmonary neuroendocrine carcinoma, was approved by China's National Medical Products Administration Center for Drug Evaluation to be included in the priority review and approval process.

The company stated that this milestone signifies the formal locking in of the commercialization timeline for LBL-024, with a clear and anticipated timeline for market approval.

Concurrently, the company is actively advancing various pre-commercialization preparatory work.